Format
Items per page
Sort by

Send to:

Choose Destination

Results: 16

1.

The use of anti-fibrinolytic agents in patients with HHT: a retrospective survey.

Zaffar N, Ravichakaravarthy T, Faughnan ME, Shehata N.

Ann Hematol. 2015 Jan;94(1):145-52. doi: 10.1007/s00277-014-2169-y. Epub 2014 Jul 27.

PMID:
25064693
2.

Tranexamic acid for epistaxis in hereditary hemorrhagic telangiectasia patients: a European cross-over controlled trial in a rare disease.

Gaillard S, Dupuis-Girod S, Boutitie F, Rivière S, Morinière S, Hatron PY, Manfredi G, Kaminsky P, Capitaine AL, Roy P, Gueyffier F, Plauchu H; ATERO Study Group.

J Thromb Haemost. 2014 Sep;12(9):1494-502. doi: 10.1111/jth.12654. Epub 2014 Jul 29.

PMID:
25040799
3.

Treatment of epistaxis in hereditary hemorrhagic telangiectasia with tranexamic acid - a double-blind placebo-controlled cross-over phase IIIB study.

Geisthoff UW, Seyfert UT, Kübler M, Bieg B, Plinkert PK, König J.

Thromb Res. 2014 Sep;134(3):565-71. doi: 10.1016/j.thromres.2014.06.012. Epub 2014 Jun 16.

PMID:
25005464
4.

Tranexamic acid and bevacizumab in hereditary hemorrhagic telangiectasia patients presenting with epistaxis.

Lacout A, Marcy PY, El Hajjam M, Lacombe P.

Cutis. 2013 Apr;91(4):173-4. No abstract available.

PMID:
23763075
5.

Lifestyle and dietary influences on nosebleed severity in hereditary hemorrhagic telangiectasia.

Silva BM, Hosman AE, Devlin HL, Shovlin CL.

Laryngoscope. 2013 May;123(5):1092-9. doi: 10.1002/lary.23893. Epub 2013 Feb 12.

PMID:
23404156
6.

Tranexamic acid-bevacizumab synergy in HHT patients presenting pulmonary arteriovenous malformations.

Lacout A, Marcy PY, El Hajjam M, Lacombe P.

Med Hypotheses. 2012 Nov;79(5):605-6. doi: 10.1016/j.mehy.2012.07.031. Epub 2012 Sep 5.

PMID:
22959314
8.

Hereditary haemorrhagic telangiectasia (HHT): negotiating between the Scylla of bleeding and Charybdis of thrombosis.

Ghosh K, Ghosh K.

Thromb Haemost. 2008 Jul;100(1):162-4. doi: 10.1160/TH08-01-0044. No abstract available.

PMID:
18612556
9.

[Treatment of epistaxes in hereditary haemorrhagic telangiectasia (Rendu-Osler-Weber disease) with tranexamic acid].

Morales-Angulo C, Pérez del Molino A, Zarrabeitia R, Fernández A, Sanz-Rodríguez F, Botella LM.

Acta Otorrinolaringol Esp. 2007 Apr;58(4):129-32. Spanish.

10.

Therapeutic action of tranexamic acid in hereditary haemorrhagic telangiectasia (HHT): regulation of ALK-1/endoglin pathway in endothelial cells.

Fernandez-L A, Garrido-Martin EM, Sanz-Rodriguez F, Ramirez JR, Morales-Angulo C, Zarrabeitia R, Perez-Molino A, Bernabéu C, Botella LM.

Thromb Haemost. 2007 Feb;97(2):254-62.

PMID:
17264955
11.

[Efficacy of tranexamic acid in a patient with hereditary hemorrhagic telangiectasia and massive epistaxis].

Pérez del Molino A, Zarrabeitia R, Fernández A, Botella LM.

Med Clin (Barc). 2004 Jun 19;123(3):118-9. Spanish. No abstract available.

PMID:
15225479
12.

Rendu-Osler-Weber disease: experience with 56 patients.

Sabbà C, Pasculli G, Cirulli A, Gallitelli M, Virgilio G, Guastamacchia E, Resta F, Palasciano G.

Ann Ital Med Int. 2002 Jul-Sep;17(3):173-9.

PMID:
12402665
13.

Tranexamic acid in hereditary hemorrhagic telangiectasia.

Lozano M.

N Engl J Med. 2002 Feb 7;346(6):457. No abstract available.

14.

Efficacy of unusually high doses of tranexamic acid for the treatment of epistaxis in hereditary hemorrhagic telangiectasia.

Sabbà C, Gallitelli M, Palasciano G.

N Engl J Med. 2001 Sep 20;345(12):926. No abstract available.

15.

Intranasal tranexamic acid treatment for severe epistaxis in hereditary hemorrhagic telangiectasia.

Klepfish A, Berrebi A, Schattner A.

Arch Intern Med. 2001 Mar 12;161(5):767. No abstract available.

PMID:
11231712
16.

[Chronic, hemorrhage-induced iron deficiency anemia in Osler disease].

Fontana S, Lämmle B.

Ther Umsch. 1999 Sep;56(9):526-8. German.

PMID:
10517126
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk